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The draft legislation for Traditional Chinese Medicine (TCM) sparked a new wave of debate and 
discussion about the future of complementary and alternative medicine in mainland China. This 
is by no means the first time scholars and physicians debate how the government should 
intervene with TCM. Banning TCM, at least from the public sector, was very much on the media 
agenda as early as the 1910s and 1920s. This round of TCM controversy came at a time when 
healthcare expenditure rapidly increased over the last decade and costs associated with drugs 
constitute a much larger part of healthcare expenditure in China than in developed nations. Will 
the government’s investment in TCM provide a possible solution to the rising health care 
expenditure? Or shall the payers hold TCM to the same drug trial standard as modern medicine? 
Is it fair to ask taxpayers to finance TCM drugs that could not survive a Phase III trial required for 
modern drugs? 
In this issue, two researchers with background in traditional Chinese medicine contributed their 
prompt feedback to the draft version of the TCM legislation. They both noted the inadequacy of 
existing TCM workforce training: apprenticeship-based education and experience-based 
practice. Even if we fully assume that the theory of TCM is as credible as modern medicine, a 
training system largely reliant on apprenticeship could not serve the need of a modern society 
where most citizens need clinical care from cradle to grave. Secondly, from the perspective of 
pharmacoeconomics, the perpetual curse for herbal medicine lies in the fact that “natural 
drugs” are intrinsically hard to patent: spending millions of dollars on clinical trials to prove the 
therapeutic effect of orange peel will not bring much profit for the sponsor of the trial, since 
patients can simply respond to the trial results by preserving orange peel themselves. If the 
current model of trial sponsorship defies the private sector’s motive of testing natural drugs, then 
some alternative mechanisms could be introduced to encourage the research and 
development in this field.     
Many people realize that China is not alone in dealing with its traditional or folk medicine. In this 
issue, Dr. Pan noted the Japanese approach toward its traditional medicine. Many pondered 
why Japan dominated the international TCM drug market (“TCM drug” here is broadly defined, 
including Korean and Japanese branches deeply rooted in TCM), and our authors’ discussion of 
standardizing the pharmaceutical regulation of TCM could provide one clue for improving the 
international competitiveness of China-made TCM drugs: quality of production and authenticity 
of drugs. 
One very common research gap lies in the lack of debate about other complementary and 
alternative medicine in China: traditional Tibetan medicine, traditional Uighur medicine, 
traditional Mongolian medicine, etc. Whatever policy and procedure are implemented for TCM, 
they should be applicable for the traditional medicine practiced among minority ethnicities as 
well.  
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